Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodimerization or CDC25A binding to 14-3-3ε. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH.sub.2 (SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO.sub.3.sup.2−)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH.sub.2 (SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO.sub.3.sup.2−)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH.sub.2 (SEQ ID NO: 3).

Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I)

##STR00001##

or a pharmaceutically or veterinary acceptable salt thereof, wherein:
R.sub.1 R.sub.2 and R.sub.3 have particular meaning; and (b) one or more drugs selected from the group consisting of i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof,

##STR00002##

wherein R.sub.5 and R.sub.6 have particular meaning, ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator), and iii) a Signal transducer and activator of transcription 3 (STAT3) inhibitor. Particular combinations and single pharmaceutical compositions and kits of parts are disclosed. These combinations, single pharmaceutical compositions and kits of parts are for use in the treatment and/or prevention of an inflammatory neurological disease or condition which can result in the destruction or degeneration of axons or myelin in a subject in need thereof

Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I)

##STR00001##

or a pharmaceutically or veterinary acceptable salt thereof, wherein:
R.sub.1 R.sub.2 and R.sub.3 have particular meaning; and (b) one or more drugs selected from the group consisting of i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof,

##STR00002##

wherein R.sub.5 and R.sub.6 have particular meaning, ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator), and iii) a Signal transducer and activator of transcription 3 (STAT3) inhibitor. Particular combinations and single pharmaceutical compositions and kits of parts are disclosed. These combinations, single pharmaceutical compositions and kits of parts are for use in the treatment and/or prevention of an inflammatory neurological disease or condition which can result in the destruction or degeneration of axons or myelin in a subject in need thereof

The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (IL)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of NF-κB and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK signaling pathway, and suppresses the expression of a RANKL or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (TRAP), cathepsin K, or TNF receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration. Moreover, the peptide of the present invention can contribute to osteoblast differentiation by promoting the expression of osteoblast differentiation markers such as osteocalcin (OCN), osteoprotegerin (OPG), bone sialoprotein (BSP), or osteopontin (OPN). Therefore, the superior activity and stability of the peptide of the present invention are useful for medicines, sanitary aids, or cosmetics.

The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (IL)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of NF-κB and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK signaling pathway, and suppresses the expression of a RANKL or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (TRAP), cathepsin K, or TNF receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration. Moreover, the peptide of the present invention can contribute to osteoblast differentiation by promoting the expression of osteoblast differentiation markers such as osteocalcin (OCN), osteoprotegerin (OPG), bone sialoprotein (BSP), or osteopontin (OPN). Therefore, the superior activity and stability of the peptide of the present invention are useful for medicines, sanitary aids, or cosmetics.

A compound bitter melon peptide (BMP) oral medicine for activating insulin and treating diabetes, including 20-30 parts by weight of BMP powder, 4-6 parts by weight of Panax quinquefolius, 10-12 parts by weight of Astragalus membranaceus, 3-5 parts by weight of Ganoderma lucidum powder, 8-10 parts by weight of Dioscorea opposita powder, 10-15 parts by weight of wheat bran, 10-12 parts by weight of Psidium guajava leaf powder, 5-10 parts by weight of onion extract, 5-10 parts by weight of Lycium barbarum, 12-15 parts by weight of Gynura procumbens extract, 1-2 parts by weight of coix seed, 5-8 parts by weight of konjac glucomannan, 8-10 parts by weight of lotus leaf and 5-8 parts by weight of xylo-oligosaccharide. A method for preparing the compound bitter melon peptide (BMP) oral medicine is also provided.

A compound bitter melon peptide (BMP) oral medicine for activating insulin and treating diabetes, including 20-30 parts by weight of BMP powder, 4-6 parts by weight of Panax quinquefolius, 10-12 parts by weight of Astragalus membranaceus, 3-5 parts by weight of Ganoderma lucidum powder, 8-10 parts by weight of Dioscorea opposita powder, 10-15 parts by weight of wheat bran, 10-12 parts by weight of Psidium guajava leaf powder, 5-10 parts by weight of onion extract, 5-10 parts by weight of Lycium barbarum, 12-15 parts by weight of Gynura procumbens extract, 1-2 parts by weight of coix seed, 5-8 parts by weight of konjac glucomannan, 8-10 parts by weight of lotus leaf and 5-8 parts by weight of xylo-oligosaccharide. A method for preparing the compound bitter melon peptide (BMP) oral medicine is also provided.

This disclosure generally relates to therapeutic conjugates that covalently bind to a biological target. Methods of administering the compositions to a subject in need thereof are also provided herein.

Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+cells are provided as well.

Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+cells are provided as well.